Dennis Urbaniak

Healthcare & life sciences exec focusing on digital health for addiction. EVP Digital Health Orexo AB

[Orexo @OrexoABpubl]

Glad to announce CEO Nikolaj Sørensen was elected as board member at Gesynta Pharma´s AGM, this week. Gesynta is an important partner as they own the rights to OX-MPI. A drug candidate with orphan drug designation status for the development of a treatment for systemic sclerosis.

[Orexo @OrexoABpubl]

Congrats @Ethypharm for bringing deprexis® to France! This highly individualized digital therapeutic is backed up by strong clinical evidence in 12 RCTs & has the potential to help patients suffering from symptoms of mild to severe #depression @GAIA_COM https://t.co/SwgFue16Xp

[Health Radio Online @HealthProRadio]

Digital Therapeutics for People Living with Moderate to Severe Depression
Read more: https://t.co/koKoEYzT6L
#Orexo

[Orexo @OrexoABpubl]

Today CEO Nikolaj Sørensen presented at the Stockholm Corporate Life Science Days. The Q&A session was held by @cstjerngren who among others asked about the potential with our novel Drug Delivery platform amorphOX™. #transformation #lifesciences

[Dennis Urbaniak @DUrbaniak]

@LinWriter @OrexoABpubl @SHRM @LinWriter it was my pleasure! Thank you for your work on this important topic.

[Orexo @OrexoABpubl]

#Orexo and @Lyfebulb are delighted to announce the winner of the 2020 Innovation Challenge as Rohan Dixit, of @getlief, for their wearable patch that monitors heart rate variability. More info here: https://t.co/eiX7w5WGqq
#digitaltherapeutics #mentalhealth

[Orexo @OrexoABpubl]

“To shed light on lives affected by addiction and the road to recovery” – our mission and reason for setting up a blog platform on which to share the stories and insights from individuals coping with #addiction, #recovery and #MentalHealth. Read the blog➡️https://t.co/ZHzSlM4ZMi

[Christina Nyquist @cnyquist3]

Chronic disease costs of those w/comorbid mental illness are 2 to 3x higher. Milliman says $37 to $68 billion/year could be saved by integrating medical & behavioral care. Digital therapeutics could integrate mental health into primary care & ERs #miaw2020 https://t.co/WosiX6966T

[Christina Nyquist @cnyquist3]

Covid has increased the prevalence of anxiety. Digital therapeutics (DTx) offer 24/7 access to evidence based therapy. Clinical research shows that over 70% of Generalized Anxiety Disorder patients achieved remission after 10 weeks of DTx usage. #miaw2020 @mentalhealtham

[Christina Nyquist @cnyquist3]

As we observe Mental Illness Awareness Wk, note Panic Disorder appears 2.5x more often in women. Treatment with the DIgital Therapeutic (DTx) Freespira enabled more than 80% of participants to be panic free. #MIAW2020 @MentalHealthAm https://t.co/qXeLDxpQEs

[Christina Nyquist @cnyquist3]

Minorities experience bipolar disorder at similar rates to the overall population (about 4% of adults). However, African Americans are less likely to receive mood stabilizing treatment. #miaw2020 @TheBlackCaucus @MentalHealthAm https://t.co/ZDzTSqmFFT

[Christina Nyquist @cnyquist3]

See Sec. 2c: “increase the availability of ....online mental health and substance-use tools.” What does this mean for digital therapeutics that offer effective treatments for depression or other mental health conditions? #digitaltherapeutics #miaw2020 https://t.co/05fEjjTthV

[Christina Nyquist @cnyquist3]

Innovation is critical but so is fighting fraud. That’s why our digital therapeutic proposal for Medicare coverage limits it to DTx products HHS publishes on approved website list. #digitaltherapeutics @pminemyer https://t.co/gulALU5lP3

[Christina Nyquist @cnyquist3]

Warning: Minorities with bipolar disorder are more likely to be misdiagnosed with schizophrenia, conduct disorder or antisocial behavior. #miaw2020 #7days7ways @theBlackCaucus https://t.co/ElsBqgGVaN

[Dennis Urbaniak @DUrbaniak]

Nice piece today by Inc. Magazine on checking on how much "gas is in the tank". Stress can drive increased mental health and substance abuse challenges so careful attention to your the needs of your team has never been more important. https://t.co/zdXj4OaZeq

[Karin Hehenberger MD PhD @KarinLyfebulb]

APPLY NOW to our virtual #InnovationChallenge in partnership w/ @OrexoABpubl @Lyfebulb is seeking companies w/ solutions to support #recovery #addiction using #healthcareIT #consumerproducts #devices #LyfebulbOrexo20 #recoveryinnovation https://t.co/8regSwv7hi

[Lyfebulb @Lyfebulb]

APPLY NOW to our virtual Innovation Challenge in partnership with @OrexoABpubl.. We are seeking #patiententrepreneurs with solutions to support #recovery from #addiction using #healthcareIT, #consumerproducts and #devices #LyfebulbOrexo20 #recoveryinnovation

[Orexo @OrexoABpubl]

This morning we released positive results from the human PK study of our nalmefene opioid overdose rescue medication, OX125, which may provide an effective response to long acting opioids such as fentanyl.
Read the release here: https://t.co/bjXGRLDNzI #addiction #opioidcrisis

[Orexo @OrexoABpubl]

Orexo DTx -> We now accept applications to our #innovation challenge in partnership with @Lyfebulb ! Applicants should be Patient Entrepreneurs - those who have been affected by a substance use disorder themselves, or as a support partner https://t.co/GSUl9UaKgu

[Orexo @OrexoABpubl]

WITH MARKS OF WISDOM SHE CONTINUES TO INSPIRE US ALL 2(2)
......Today, in her role as Medical Science Liaison at #Orexo, she play a key role in raising awareness around addiction and mental health issues. Read the full company interview here: https://t.co/acBGbQmXDL #mentalhealth